Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer | Zendy

Jennifer M. Giltnane | Zendy; Lisa Rydén | Zendy; Melissa A. Cregger | Zendy; PärOla Bendahl | Zendy; Karin Jirström | Zendy; David L. Rimm | Zendy

Open Access

Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer

Author(s) -

Jennifer M. Giltnane,

Lisa Rydén,

Melissa A. Cregger,

PärOla Bendahl,

Karin Jirström,

David L. Rimm

Publication year - 2007

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2006.08.9938

Subject(s) - tamoxifen , medicine , breast cancer , oncology , hazard ratio , epidermal growth factor receptor , estrogen receptor , tissue microarray , cancer , confidence interval

Although there is evidence for interaction between epidermal growth factor receptor (EGFR) and estrogen receptor (ER), it is still not clear how this affects response to endocrine therapies like tamoxifen. Here we assess the relationship between EGFR expression and tamoxifen response, with a new quantitative technology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research